Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients
Overview
Authors
Affiliations
The reason why most individuals with COVID-19 have relatively limited symptoms while other develop respiratory distress with life-threatening complications remains unknown. Increasing evidence suggests that COVID-19 associated adverse outcomes mainly rely on dysregulated immunity. Here, we compared transcriptomic profiles of blood cells from 103 patients with different severity levels of COVID-19 with that of 27 healthy and 22 influenza-infected individuals. Data provided a complete overview of SARS-CoV-2-induced immune signature, including a dramatic defect in IFN responses, a reduction of toxicity-related molecules in NK cells, an increased degranulation of neutrophils, a dysregulation of T cells, a dramatic increase in B cell function and immunoglobulin production, as well as an important over-expression of genes involved in metabolism and cell cycle in patients infected with SARS-CoV-2 compared to those infected with influenza viruses. These features also differed according to COVID-19 severity. Overall and specific gene expression patterns across groups can be visualized on an interactive website (https://bix.unil.ch/covid/). Collectively, these transcriptomic host responses to SARS-CoV-2 infection are discussed in the context of current studies, thereby improving our understanding of COVID-19 pathogenesis and shaping the severity level of COVID-19.
Fenn J, Madon K, Conibear E, Derelle R, Nevin S, Kundu R EBioMedicine. 2024; 111():105475.
PMID: 39667271 PMC: 11697275. DOI: 10.1016/j.ebiom.2024.105475.
Savin I, Senkova A, Goncharova E, Zenkova M, Markov A Int J Mol Sci. 2024; 25(22).
PMID: 39596028 PMC: 11594146. DOI: 10.3390/ijms252211958.
Drury R, Camara S, Chelysheva I, Bibi S, Sanders K, Felle S Nat Commun. 2024; 15(1):3402.
PMID: 38649734 PMC: 11035709. DOI: 10.1038/s41467-024-47463-6.
Lei H Viruses. 2024; 16(2).
PMID: 38399976 PMC: 10891603. DOI: 10.3390/v16020201.
Global analysis of the abundance of AU-rich mRNAs in response to glucocorticoid treatment.
Muazzen Z, Moghrabi W, Bakheet T, Mahmoud L, Al-Saif M, Khabar K Sci Rep. 2024; 14(1):913.
PMID: 38195703 PMC: 10776588. DOI: 10.1038/s41598-024-51301-6.